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Abstract: Background: Low 25(OH) vitamin D levels have been associated with several autoimmune
diseases and recently with autoimmune thyroiditis (AT). The aim of the study was to investigate the
association of AT with low 25(OH) vitamin D levels in the elderly. Methods: One hundred sixty-eight
elderly subjects (mean age: 81.6 ± 9.4 years) were enrolled. Serum levels of 25(OH) vitamin D,
anti-thyroid peroxidase (TPO-Ab), anti-thyroglobulin (TG-Ab) antibodies, free triiodothyronine (FT3),
free thyroxine (FT4) and thyroid stimulating hormone (TSH) were measured. Results: The prevalence
of AT was significantly higher in subjects with vitamin D deficiency (25(OH) vitamin D < 20 ng/mL)
when compared with subjects with normal 25(OH) vitamin D (25(OH) vitamin D ≥ 20 ng/mL) levels
(28% vs. 8%, respectively, p = 0.002). Patients with AT and vitamin D deficiency had a comparable
hormonal profile compared to patients with AT and vitamin D sufficiency in terms of TSH (p = 0.39),
FT3 (p = 0.30), FT4 (p = 0.31), TG-Ab (0.44) and TPO-Ab (0.35). Interestingly, a significant correlation
between 25(OH) vitamin D and TPO-Ab (r = −0.27, p = 0.03) and FT3 (r = 0.35, p = 0.006) has been
found in subjects with AT while no correlation was found between 25(OH) vitamin D levels and
TG-Ab (r = −0.15, p = 0.25), TSH (r = −0.014, p = 0.09) and FT4 (r = 0.13, p = 0.32). Conclusions:
These findings suggest that vitamin D deficiency was significantly associated with AT in the elderly.
Therefore, the screening for AT should be suggested in subjects with vitamin D deficiency.
Keywords: vitamin D; autoimmune thyroid disease; elderly; lifestyle; environment
1. Introduction
Humans derive vitamin D from cutaneous synthesis (in the form of cholecalciferol (D3)), from diet
(in the form of D3) and from nutritional supplements in the form of D3 or ergocalciferol (D2) [1]. Thanks
to the exposure to ultraviolet B radiation (UVB), 7-dehydrocholesterol is converted to pre-vitamin
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D3 in the skin, which is in turn converted to vitamin D3. After ingestion or synthesis, vitamin D is
hydroxylated in the liver by Cytochrome P450 Family 2 Subfamily R Member 1 (CYP2R1) to form
25 hydroxyvitamin D (25(OH)D2 or 25(OH)D3), its major circulating form, which has little biological
activity. The 25(OH)D is converted in the kidney by Cytochrome P450 Family 27 Subfamily B Member 1
(CYP27B1), to its bioactive hormonal metabolite 1,25 dihydroxy-vitamin D (1,25(OH)2D or calcitriol).
The 25(OH)D 1α hydroxylase has been also found in extrarenal sites including placenta, monocytes and
macrophages [1,2]. The 1,25(OH)2D binds the nuclear vitamin D receptor, which heterodimerizes with
the retinoid X receptor and binds to vitamin D–responsive elements near target genes [3]. The main
role of vitamin D is to preserve calcium and phosphorus homeostasis in order to maintain bone
health [4]. Recent evidence reported numerous extra-skeletal effects of 25(OH) vitamin D which may
also contribute to the pathogenesis of several non-skeletal disorders [5]. In particular, 25(OH) vitamin D
has been demonstrated to have a role in thyroid disease. In fact, the vitamin D3 receptor and the
receptor for the thyroid hormone have been reported to have a similar molecular structure, which was
due to two regions that they have in common: the first is a 70-amino-acid, cysteine-rich sequence and
the second region is a 62-amino-acid one located towards the carboxyl terminus of the protein [6].
Emerging, although still provisional, evidence also suggests a possible role for 25(OH) vitamin D in the
pathogenesis of autoimmune thyroiditis (AT). Vitamin D deficiency, certain vitamin D receptor (VDR)
gene polymorphisms, and alterations of vitamin D binding proteins (VDB) and of their genes may be
involved in the onset of AT [7]. Gene polymorphisms of numerous proteins and enzymes associated
with vitamin D functions, such as VDR, DPB, CYP27B1 and CYP2R1, have been found to be associated
with thyroid autoimmunity susceptibility [7,8]. Lower vitamin D levels (<10 ng/mL) have been found
to be more common in patients with AT compared to healthy controls [9]. The same conclusions
were reached by Tamer et al. [7] reporting, in patients with vitamin D insufficiency (<30 ng/mL),
a greater chance to have AT than the healthy population. However, several studies reported negative
results regarding the association of vitamin D and AT. In particular, no association between vitamin D
deficiency and AT was found by Goswami et al. [10] in a study performed in a population of Asian
Indians. Effraimidis et al. [11] reported similar results in a study performed in the Amsterdam AT
cohort. This cohort was followed up for five years. At the end of the follow-up no association was
found between AT and low vitamin D levels.
In polycystic ovary syndrome, we have demonstrated that the levels of 25(OH) vitamin
D were significantly lower in women with Polycystic Ovary Syndrome (PCOS) and AT when
compared to women with PCOS and without AT, although no correlation was found between 25(OH)
vitamin D and anti-thyroid peroxidase antibodies (TPO-Ab), anti-thyroglobulin (TG-Ab) antibodies,
free triiodothyronine (FT3), free thyroxine (FT4) and thyroid stimulating hormone (TSH) levels [12].
The main limit of these studies is that the association of 25(OH) vitamin D with AT has been
assessed in young and/or middle-aged subjects. To date, no studies have been performed in the elderly.
Based on these considerations, the aim of the current study was to investigate the association of
AT with low vitamin D levels in the elderly population, where both conditions are quite common.
2. Materials and Methods
2.1. Subjects
A total of 168 patients aged 65 years or older were retrospectively enrolled in the Division of
General Internal Medicine and Geriatrics—Italian Auxologic Institute—from April 2010 to June 2010,
after obtaining written consent. In order to avoid seasonal influences on 25(OH) vitamin D levels,
the study has been carried out in a short time-period. Exclusion criteria included: age < 65 years;
treatment with medications affecting thyroid function (L-thyroxine, antithyroid drugs, antiepileptic,
antipsychotics, amiodarone, glucocorticoid, etc.); treatment with vitamin D or calcium supplement;
administration of immunomodulatory medications.
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2.2. Clinical and Biochemical Assessment
For all subjects, body mass index (BMI) was calculated as weight (kg)/(height (m)2). After fasting
overnight for 10–12 h, blood samples were collected for the following measurements: 25(OH) vitamin D,
FT3, FT4, TSH, TG-Ab, TPO-Ab, hepatic and renal chemistries. Subjects with elevated TG-Ab and/or
TPO-Ab serum levels performed thyroid ultrasound in order to confirm the diagnosis of AT.
Serum levels of 25(OH) vitamin D were determined through electrochemiluminescence binding
assay using the Cobas analyzer (Roche Diagnostics) [13]. Serum TSH, FT3 and FT4 levels were
measured by means of electrochemiluminescence immunoassay (Roche Diagnostics). TG-Ab and
TPO-Ab measurements were undertaken by electrochemiluminescence immunoassay methods
using the Cobas analyzer (Roche Diagnostics). Modular P800 system (Roche Diagnostics) was
used for evaluation of creatinine, aspartate aminotransferase, alanine aminotransferase, glucose,
total cholesterol and triglycerides.
2.3. Definition of AT
AT was defined on the basis of serum TG-Ab (>115 IU/mL) and/or TPO-Ab (>34 IU/mL)
positivity, together with characteristic ultrasonographic features (diffuse parenchymal hypoechogenicity
and/or heterogeneous echogenic pattern of thyroid gland).
2.4. Definition of Vitamin D Deficiency
Vitamin D deficiency was defined as 25(OH)D levels < 20 ng/mL while 25(OH)D levels
≥ 20 ng/mL were considered normal [14].
2.5. Statistical Analysis
Statistical analysis was carried out using SPSS 9.0 (Chicago, IL, USA). Data are expressed as
mean ± SD (Standard Deviation). Pearson correlations were used to determine relationships between
variables. Depending on the distribution of the data, the Student’s t-test for independent samples and
the non-parametric ManneWhitney U-test for independent samples were applied to test for differences
between groups. Pearson correlations were used to determine relationships between variables.
3. Results
Clinical and biochemical variables of the entire cohort of patients stratified by 25(OH) vitamin
D levels are shown in Table 1. A total of 168 subjects (mean age 81.6 ± 9.4 years) were enrolled in
this study.
Selecting 20 ng/mL as the cut-off point, low 25(OH) vitamin D levels were detected in 70% of all
patients. The overall prevalence of AT was 23%.
We compared the prevalence of AT between patients with vitamin D deficiency (25(OH)
vitamin D < 20 ng/mL) and sufficiency (25(OH) vitamin D ≥ 20 ng/mL), finding that AT was
significantly more frequent in patients with vitamin D deficiency (28% vs. 8%, p = 0.002).
Although the prevalence of AT was higher in patients with vitamin D deficiency, the subjects
with vitamin D deficiency did not differ from subjects with vitamin D sufficiency in terms of TSH
(2.1 ± 1.9 vs. 1.8 ± 1.3 mcUI/mL, p = 0.14), FT3 (3.7 ± 1.0 vs. 4.1 ± 1.6 pg/mL, p = 0.16) and FT4
levels (15.3 ± 5.3 vs. 14.7 ± 3.1 ng/dL, p = 0.33). As expected, subjects with vitamin D deficiency were
significantly older compared to subjects with normal vitamin D levels (82.8 ± 8.4 vs. 78.8 ± 10.8 years,
p = 0.005). Further, we investigated if patients with AT and vitamin D deficiency (n = 21) had a worse
hormonal profile compared to patients with AT and vitamin D sufficiency (n = 18), but we did not
find significant differences between the two groups (TSH: 1.6 ± 0.8 vs. 1.7 ± 1.1 mcUI/mL, p = 0.39;
FT3: 4.0 ± 0.8 vs. 3.7 ± 1.0 pg/mL, p = 0.30; FT4: 15.2 ± 3.0 vs. 14.3 ± 3.3 ng/dL, p = 0.31; TG-Ab:
293.7 ± 203.0 vs. 303.6 ± 210.1, p = 0.44; TPO-Ab: 252.4 ± 180.0 vs. 229.7 ± 193.3, p = 0.35).
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In addition, we focused on patients with AT in order to investigate if vitamin D levels were
associated with the grade of severity of AT in the overall population. In this subgroup Pearson
coefficient analyses revealed a significant correlation of 25(OH) vitamin D levels with TPO-Ab
(r = −0.27, p = 0.03) and FT3 (r = 0.35, p = 0.006) (Figure 1), while no correlation was found with
TG-Ab (r = −0.15, p = 0.25), TSH (r = −0.014, p = 0.09) and FT4 (r = 0.13, p = 0.32).
Table 1. Clinical and hormonal data stratified according to the vitamin D levels (mean ± SD).
Parameters Total (n = 168)
Vitamin D Deficiency
(25(OH) Vitamin D
< 20 ng/mL) (n = 116)
Vitamin D Sufficiency
(25(OH) Vitamin D
≥ 20 ng/mL) (n = 52)
p-Value
Age (years) 81.6 ± 9.4 82.8 ± 8.4 78.8 ± 10.8 0.005
25(OH) vitamin D
(ng/mL) 16.4 ± 15.6 7.6 ± 4.0 33.3 ± 19.6 <0.01
BMI (kg/m2) 29.8 ± 15.2 28.7 ± 8.6 32.4 ± 24.1 0.12
Glycemia (mg/dL) 102.4 ± 32.2 104.2 ± 33.2 101.5 ± 31.8 0.31
Creatinine (mg/dL) 1.1 ± 0.6 1.1 ± 0.7 0.9 ± 0.3 0.04
AST (UI/L) 19.9 ± 7.9 19.1 ± 6.4 21.7 ± 10.4 0.30
ALT (UI/L) 17.6 ± 11.7 16.9 ± 10.7 19.1 ± 13.7 0.13
Total Cholesterol
(mg/dL) 173.8 ± 44.6 167.0 ± 41.9 176.9 ± 45.6 0.09
Triglycerides (mg/dL) 113.9 ± 7.8 104.7 ± 40.1 118.1 ± 82.1 0.13
TSH (mcUI/mL) 2.1 ± 0.9 2.1 ± 1.9 1.8 ± 1.3 0.14
FT3 (pg/mL) 3.3 ± 0.4 3.7 ± 1.0 4.1 ± 1.6 0.16
FT4 (ng/dL) 15.1 ± 4.7 15.3 ± 5.3 14.7 ± 3.1 0.33
TPO-Ab (IU/mL) 105 ± 45.9 117 ± 57.6 69.1 ± 19.8 0.01
TG-Ab (IU/mL) 121 ± 47.0 128 ± 55.7 101 ± 27.4 0.08
AT prevalence (%) 23 28 8 0.02
Int. J. Environ. Res. Public Health 2016, 13, 850 4 f 6 
 
(mg/dL) 
TSH (mcUI/mL) 2.1 ± 0.9 2.1 ± 1.9 1.8 ± 1.3 0.14 
FT3 (pg/mL) 3.3 ± 0.4 3.7 ± 1.0 4.1 ± 1.6 0.16 
FT4 (ng/dL) 15.1 ± 4.7 15.3 ± 5.3 14.7 ± 3.1 0.33 
TPO-Ab (IU/mL) 105 ± 45.9 117 ± 57.6 69.1 ± 19.8 0.01 
TG-Ab (IU/mL) 121 ± 47.0 128 ± 55.7 101 ± 27.4 0.08 
AT prevalence (%) 23 28 8 0.02 
Selecting 20 ng/mL as the cut-off point, low 25(OH) vitamin D levels were detected in 70% of all 
patients. The overall prevalence of AT was 23%.  
We compared the prevalence of AT between patients with vitamin D deficiency (25(OH) 
vitamin D < 20 ng/mL) and sufficiency (25(OH) vitamin D ≥ 20 ng/mL), finding that AT was 
significantly more frequent in patients with vitamin D deficiency (28% vs. 8%, p = 0.002). 
Although the prevalence of AT was higher in patients with vitamin D deficiency, the subjects 
with vitamin D deficiency did not differ from subjects with vitamin D sufficiency in terms of TSH 
(2.1 ± 1.9 vs. 1.8 ± 1.3 mcUI/mL, p = 0.14), FT3 (3.7 ± 1.0 vs. 4.1 ± 1.6 pg/mL, p = 0.16) and FT4 levels 
(15.3 ± 5.3 vs. 14.7 ± 3.1 ng/dL, p = 0.33). As expected, subjects with vitamin D deficiency were 
significantly older compared to subjects with normal vitamin D levels (82.8 ± 8.4 vs. 78.8 ± 10.8 years, 
p = 0.005). Further, we investigated if patients with AT and vitamin D deficiency (n = 21) had a worse 
hormonal profile compared to patients with AT and vitamin D sufficiency (n = 18), but we did not 
find significant differences between the two groups (TSH: 1.6 ± 0.8 vs. 1.7 ± 1.1 mcUI/mL, p = 0.39; 
FT3: 4.0 ± 0.8 vs. 3.7 ± 1.0 pg/mL, p = 0.30; FT4: 15.2 ± 3.0 vs. 14.3 ± 3.3 ng/dL, p = 0.31; TG-Ab:  
293.7 ± 203.0 vs. 303.6 ± 210.1, p = 0.44; TPO-Ab: 252.4 ± 180.0 vs. 229.7 ± 193.3, p = 0.35). 
In addition, we focused on patients with AT in order to investigate if vitamin D levels were 
associated with the grade of severity of AT in the overall population. In this subgroup Pearson 
coefficient analyses revealed a significant correlation of 25(OH) vitamin D levels with TPO-Ab  
(r = −0.27, p = 0.03) and FT3 (r = 0.35, p = 0.006) (Figure 1), while no correlation was found with TG-Ab 
(r = −0.15, p = 0.25), TSH (r = −0.014, p = 0.09) and FT4 (r = 0.13, p = 0.32). 
 
Figure 1. Correlations between 25(OH)D concentration and TPO-Ab (r = −0.27, p = 0.03) (A) and FT3 
(r = 0.35, p = 0.006) (B). 
4. Discussion 
The main finding of this study was that elderly patients with vitamin D deficiency had a 
significantly higher prevalence of AT compared to elderly patients with vitamin D sufficiency. These 
results were in agreement with previous studies in younger populations [8]. Further, 25(OH) 
vitamin D levels were significantly correlated with FT3 and TPO-Ab levels in the cohort of patients 
with AT. 
The prevalence of vitamin D deficiency (70%) was high in our elderly population, although this 
value is consistent with the results reported in European studies assessing vitamin D deficiency in 
Figure 1. Correlations between 25(OH)D concentration and TPO-Ab (r = −0.27, p = 0.03) (A) and FT3
(r = 0.35, p = 0.006) (B).
4. Discussion
The main finding of this study was that elderly patients with vitamin D deficiency had
a significantly higher prevalence of AT compared to elderly patients with vitamin D sufficiency.
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These results were in agreement with previous studies in younger populations [8]. Further, 25(OH)
vitamin D levels were significantly correlated with FT3 and TPO-Ab levels in the cohort of patients
with AT.
The prevalence of vitamin D deficiency (70%) was high in our elderly population, although this
value is consistent with the results reported in European studies assessing vitamin D deficiency in the
elderly [15–18]. This strict interaction between vitamin D deficiency and AT has been also suggested by
Tamer et al. [7], who demonstrated an increased prevalence of vitamin D deficiency (25(OH) vitamin D
≤ 10 ng/mL) in patients with AT. These findings can be explained by molecular evidence indicating
a role of vitamin D in the pathogenesis of autoimmune diseases. Vitamin D deficiency has been recently
considered as an environmental trigger of AT [7,9,19].
The Vitamin D receptor (VDR) is an intracellular receptor that is expressed by human immune cells,
such as macrophages, dendritic cells, and T and B lymphocytes, although the main target is represented
by dendritic cells (DC) [20,21]. The immunomodulatory action of 1,25(OH)2D is expressed thanks to
the binding of 1,25(OH)2D to its receptor [22]. In particular 1,25(OH)2D inhibits DC maturation and
the production of DC-derived cytokines, such as IL-12 and IL-23. This effect of 1,25(OH)2D prompts
the T cells to differentiate towards the Th2 phenotype, rather than to the Th1 and Th17 phenotypes [23].
Moreover, vitamin D promotes the release of DC-derived IL-10 release which has tolerogenic properties
and reduces the production of inflammatory Th1 cytokines, such as IL-2 and IFN-γ, which promote
cell-mediated cytotoxicity responsible for thyroid destruction in AT [23]. Finally, several functional
polymorphisms in the VDR gene or vitamin D binding protein (VDB) have been involved in the
pathogenesis of AT. In particular, the polymorphism of VDB has been associated with Graves’ disease
both in the Polish and Japanese populations [24,25]. A meta-analysis of eight studies suggested that
the Bsml or Taql VDR polymorphism may be involved in the pathogenesis of AT [26]. Polymorphisms
of the CYP27B1 gene have been also reported to have a role in the pathogenesis of AT [27].
The degree of vitamin D deficiency has been reported to have a tight relationship with antibody
levels and with thyroid hormones, thus suggesting that vitamin D levels may have a direct role in
determining the grade of severity of autoimmune disease and of the consequent hypothyroidism [28,29].
In our study we found that 25(OH) vitamin D levels significantly correlated with TPO-Ab and FT3,
while we failed to find any association of 25(OH) vitamin D levels with TG-Ab, FT4 and TSH.
5. Conclusions
In conclusion, within the limitations of a cross-sectional design, the present study shows that
vitamin D deficiency was associated with AT in the elderly. Future longitudinal cohort studies along
with prospective interventional trials may contribute to better clarifying if vitamin D supplementation
may have a role in the prevention and/or therapy of AT in the elderly.
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